AUSTRALIAN CANCER DRUG SECURES $730M DEAL

Written on the 1 February 2016

AUSTRALIAN CANCER DRUG SECURES $730M DEAL

A NEW cancer drug developed in Australia has been licensed to US pharmaceutical company Merck in a $730 million deal.

Merck will advance the drug to clinical trials, in a bid to commercialise the cancer and non-cancer blood disorder treatment worldwide.

The financial returns will be shared between the Cancer Therapeutics CRC and its research partners CSIRO, Monash University, Peter MacCallum Cancer Centre and the Walter and Eliza Hall Insititute, as well as the Wellcome Trust and Cancer Research Technology in the UK.

CSIRO research partner Dr Tom Peat says the drug is designed to inhibit the protein PRMT5, which is linked to a range of cancers including mantle cell lymphoma, lung cancer, breast cancer and colorectal cancer.

"Patients who have these types of cancers often have high levels of this protein, which is unfortunately also linked to poor survival rates," Dr Peat says.

"Using our recombinant protein production facilities, we were able to produce samples of these proteins, crystallise them for structure based drug design and support the consortium's pre-commercial investigations and trials.

"Access to high quality protein is absolutely critical in structural biology approaches to drug discovery, and CSIRO is pleased to be able to contribute this key capability."

He says the research consortium was able to develop a drug that binds to this protein, allowing it to target cancerous cells.

PRMT5 inhibitors also have the ability to switch on important genes in the development of blood, which could provide disease-modifying treatment options for patients with blood disorders like sickle cell disease and beta thalassemia.

"We're thrilled to be part of this development, which has the potential to make a real difference for patients here in Australia and around the globe," Dr Peat says.

 


Latest News

HOW TO LEAD A BETTER BUSINESS WITH YOUR PARTNER

PEOPLE say that starting your own business is one of the greatest challenges you can face. Edward and Rebecca Plan...

CORPORATE TRAVEL MANAGEMENT NOTCHES UP 23 YEARS OF CONSECUTIVE GROWTH

CORPORATE Travel Management (ASX: CTD) has reported its strongest ever full-year results, with a net profit increa...

REPORTING SEASON WRAP: TUESDAY HIGHLIGHTS

* BHP Billiton (ASX: BHP) reported full year net profit of $7.42 billion compared to a $8 billion loss in the previou...

GREENCROSS PLANS MORE IN STORE VET CLINICS ON THE BACK OF A 21.5 PER CENT PROFIT RISE

VETERINARY services provider Greencross Limited (ASX: GXL) has reported an increase in profit of 21.5 per cent to ...

Related News

DARK DAYS AHEAD FOR AUSTRALIAN RETAIL AS REPORT FORECASTS MAJOR INDUSTRY ROUT

ALMOST 1,600 retail businesses are at risk of imminent collapse, including 21 major retailers with turnovers of more ...

REPORTING SEASON WRAP: MONDAY HIGHLIGHTS

* FORTESCUE Metals (ASX: FMG) reported net profit after tax (NPAT) of $2.64 billion for the year to June 30, up fr...

WESFARMERS BOOKS BUMPER PROFIT BUT SUPERMARKET WAR HITS COLES' BOTTOM LINE

SUPERMARKET giant Coles has posted its biggest slide in earnings since it was acquired by Wesfarmers (ASX: WES) 10 ye...

ANALYSTS PREDICT WHAT AUSSIE LIVING IS LIKELY TO BECOME IN THE NEXT CENTURY

AS THE Australian population continues to grow, analysts are predicting what the country is likely to look like wi...

BOOK YOUR FUNCTION SPACE HERE

 

 

 

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter